Last updated on February 2020

Study of Intravenous ATYR1923 for Pulmonary Sarcoidosis


Brief description of study

This randomized, double-blind, placebo-controlled, study will evaluate the safety, tolerability, immunogenicity, pharmacokinetic (PK), and preliminary efficacy of multiple ascending doses of IV ATYR1923 in patients with pulmonary sarcoidosis undergoing a protocol-guided oral corticosteroid (OCS) tapering regimen.This study will consist of 3 staggered multiple dose cohorts. Each eligible participant will participate in only one cohort during the study. Within each cohort, 12 participants will be randomized 2:1 to ATYR1923 (N=8) or placebo (N=4).

Clinical Study Identifier: NCT03824392

Find a site near you

Start Over

East Carolina University

Greenville, NC United States
2.51miles
  Connect »